In order to broaden SHOC2’s properties as a possible therapeutic target in NSCLC, we set out to identify potential synthetic lethal interactions with small molecule inhibitors by screening in the presence or absence of SHOC2. Here, SHOC2 is linked to non-small cell lung carcinoma.